QUEBEC CITY, QUEBEC--(Marketwire - June 03, 2008) - Medicago Inc. (TSX VENTURE: MDG) today announced positive results from a preclinical immunogenicity study of the Company’s H5N1 Avian Influenza VLP vaccine that was performed in ferrets, the most predictive animal model for the effectiveness of influenza vaccines in humans. Results demonstrated that a single 5-microgram dose of the Company’s H5N1 VLP vaccine induced high levels of antibodies in 100% of ferrets and met all required immunogenicity criteria of the European Union Committee for Medicinal Products for Human Use (CHMP).These criteria set by the CHMP for the approval of seasonal flu vaccines in the European Union are widely used to assess immune responses of new pandemic influenza vaccines in humans. In the case of ferrets, these criteria are useful to predict effective doses that should be tested in humans.
